艾迪注射液联合立体定向放射治疗原发性肝癌疗效观察
The analysis of therapeutic effect of primary liver cancer treated by Aidi injection combined with stereotactic radiotherapy
侯激流1
作者信息
- 1. 河南省平顶山市第二人民医院 467000
- 折叠
摘要
目的 评价艾迪注射液联合X-刀立体定向放射治疗(SRT)对原发性肝癌(PHC)的疗效.方法 107例原发性肝癌患者行SRT治疗,SRT分次量3～4 Gy,3次/周,治疗剂量40～60 Gy.57例联合艾迪注射液治疗(艾迪注射液60 ml+0.9％氯化钠溶液或5％葡萄糖溶液500ml静脉滴注,第1～21天,间隔10 d后行第2个疗程治疗).结果 艾迪联合组与SRT组总有效率、疾病控制率及1、2、3a生存率分别为:75.5％ 94.7％与72％、92％及65％、29.8％、10.S％与56％、22％、8％.两组在总有效率、疾病控制率、生存率等方面差异无统计学意义(P＞0.05);骨髓抑制发生率及生活质量方面艾迪联合组与5RT组分别为22.8％与42％及73.7％与52％,差异有统计学意义(P＜0.05).结论 艾迪注射液与SRT联合治疗原发性肝癌具有明显抗辐射、提高肝癌患者生活质量作用,值得进一步研究.
Abstract
Objective To analyze the therapeutic effect of primary liver cancer treated by Aidi injection combined with stereotactic radiotherapy SRT. Methods 50 patients with primary liver cancer were treated with X-ray SRT, and 57 patients were treated with Aidi injection combined with SRT,SRT:DT 40～60 Gy(300～400 cGy/F,3F/w, Aidi injection 60ml+ NS/5%GS 500ml,dl～dl4,the second course line spacing 10 days. Results All patients were examined with image of CT or MRI. The total effective rate(CR+PR),the disease control rate (DCR) and 1,2,3 years survival rates was 75. 5%,94. 7% vs 72%,92% and 65%,29. 8%,10. 5% VS 56%.22%, 8%, There were no differences in curative effect and survival rates( P>0.05). Bone marrow restrain incidence and life for the total effective rate was ignificantlys sever in Aidi group than in SRT group ( 22. 8%vs42% and 73. 7% vs 52%) (P< 0.05). Conclusions Aidi injection combined with SRT in the treatment of primary liver cancer can resist radiation and improve patients quality of life.
关键词
肝肿瘤/药物疗法/放射疗法/艾叶/治疗应用/抗肿瘤药(中药)/治疗应用/注射剂/立体定位技术Key words
Liver Neoplasms/drug therapy/ARTEMISIA ARGYT/therapeutic use/Antineoplastic Agents(TCD)/therapeutic use/1NJECTIO/Stereotaxic Techniques引用本文复制引用
出版年
2012
NETL
NSTL
维普
万方数据